FrancophonIA/ELRC3.0 huggingface dataset:
English: Equivalent doses of these different forms do not all produce the same levels of raltegravir in the body, so they must not be used interchangeably.
Estonian: Eri ravimvormide samaväärsed annused ei tekita organismis ühesugust raltegraviiri sisaldust, seega ei tohi neid kasutada üksteise asemel.
English: This study looked at viral loads after 24 and 48 weeks.
Estonian: Selles uuringus vaadeldi viiruskoormust 24ja 48-nädalase ravi järel.
English: Isentress does not cure HIV infection or AIDS, but it may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Isentress ei ravi HIV-nakkust ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ning AIDSiga seotud nakkuste ja haiguste teket edasi lükata.
English: Side effects in children were comparable to those in adults.
Estonian: Laste kõrvalnähud olid võrreldavad täiskasvanute kõrvalnähtudega.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Isentress have been included in the summary of product characteristics and the package leaflet.
Estonian: Isentressi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Isentress has been studied in six main studies.
Estonian: Isentressi uuriti kuues põhiuuringus.
English: • A sixth study included 26 children aged 4 weeks to 2 years who were given Isentress oral granules made into a suspension.
Estonian: • Kuuendas uuringus osales 26 last vanuses 4 nädalat kuni 2 aastat ning neile manustati Isentressi suukaudsetest graanulitest valmistatud suspensiooni.
English: What are the risks associated with Isentress?
Estonian: Mis riskid Isentressiga kaasnevad?
English: For more information about using Isentress see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Isentressi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Isentress received a conditional marketing authorisation valid throughout the European Union for Isentress on 20 December 2007.
Estonian: Isentressi on saanud müügiloa tingimusliku heakskiidu alusel, mis kehtib kogu ELis, 20. detsembril 2007.
English: • A fourth study in 802 patients who had not taken HIV treatment before showed that giving Isentress as a single dose of 1,200 mg once daily was as effective as giving 400 mg twice daily.
Estonian: • Neljandas uuringus, kus osales 802 patsienti, kellel ei olnud varem HIV-nakkust ravitud, osutus korra ööpäevas antud Isentressi 1200 mg annus sama efektiivseks kui kaks korda ööpäevas antud 400 mg annus.
English: All of the patients also took tenofovir and emtricitabine (other HIV medicines).
Estonian: Kõik patsiendid võtsid ka tenofoviiri ja emtritsitabiini (samuti HIV-ravimid).
English: • Additional supportive studies established doses that provide similar effective levels of Isentress in newborn infants as in young children.
Estonian: • Lisauuringutega tehti kindlaks annused, mis aitavad saavutada vastsündinutel Isentressi sama efektiivse sisalduse nagu väikelastel.
English: The granules are to make a mixture for babies and children to drink, the chewable tablets are for bigger children, and the 400- and 600-mg tablets are for different dose regimens in older children and adults, as recommended by the doctor.
Estonian: Graanulitest valmistatakse imikutele ja väikelastele joogisegu, närimistabletid on suurematele lastele ning 400 ja 600 mg tabletid on vanematele lastele ja täiskasvanutele, kes järgivad vastavalt arsti soovitustele erinevaid annustamisskeeme.
English: The most common side effects with Isentress (seen in between 1 and 10 patients in 100) are headache, abdominal pain (stomach ache) and nausea (feeling sick).
Estonian: Isentressi kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peavalu, kõhuvalu ja iiveldus.
English: Therefore, the effectiveness observed in adults is also expected in children.
Estonian: Seetõttu eeldatakse lastel samasugust efektiivsust nagu täiskasvanutel.
English: How does Isentress work?
Estonian: Kuidas Isentress toimib?
English: • A third study involved 566 patients who had not taken HIV treatment before and compared Isentress with efavirenz (another HIV medicine).
Estonian: • Kolmandas uuringus osales 566 patsienti, kellel ei olnud varem HIV-nakkust ravitud, ja selles võrreldi Isentressi efavirensiga (samuti HIV-ravim).
English: When the enzyme is blocked, the virus cannot reproduce normally, slowing down the spread of infection.
Estonian: Kui ensüüm on blokeeritud, on viiruse normaalne paljunemine häiritud ning infektsiooni levik organismis aeglustub.
English: The most common serious side effects are immune reconstitution syndrome (symptoms of infection caused by a recovering immune system) and rash.
Estonian: Kõige raskemad kõrvalnähud on immuunsüsteemi ülereageerimise sündroom (taastuv immuunsüsteem põhjustab infektsioonisümptomeid) ja lööve.
English: The medicine is available as tablets to be swallowed (400 and 600 mg), chewable tablets (25 and 100 mg) and sachets containing granules for an oral suspension (each sachet containing 100 mg).
Estonian: Seda turustatakse 400 ja 600 mg neelatavate tablettidena, 25 ja 100 mg närimistablettidena ja suukaudse suspensiooni graanulitena (100 mg kotikestes).
English: • Two studies involved a total of 699 ‘treatment-experienced' patients who were already receiving treatment for HIV infection that was not working.
Estonian: • Kahes uuringus osales kokku 699 varem ravitud patsienti, kelle HIV-nakkuse ravi oli olnud tulemusteta.
English: The active substance in Isentress, raltegravir, is an integrase inhibitor.
Estonian: Isentressi toimeaine raltegraviir on integraasiinhibiitor.
English: Isentress is an HIV medicine that is used in combination with other HIV medicines to treat patients who are infected with human immunodeficiency virus (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Isentress on HIV-ravim, mida kasutatakse koos teiste HIV-ravimitega, et ravida patsiente, kellel on inimese 1. tüüpi immuunpuudulikkuse viiruse (HIV-1) nakkus.
English: Isentress, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Koos teiste viirusravimitega manustatav Isentress vähendab HIVi kogust veres ja hoiab selle sisalduse väikese.
English: Isentress was as effective as efavirenz.
Estonian: Isentressi efektiivsus oli sama kui efavirensil.
English: Isentress contains the active substance raltegravir.
Estonian: Isentress sisaldab toimeainena raltegraviiri.
English: It blocks an enzyme called integrase, which is involved in a step in the reproduction of HIV.
Estonian: See blokeerib HIV-nakkuse paljunemises osaleva ensüümi integraasi.
English: For the full list of side effects and restrictions with Isentress, see the package leaflet.
Estonian: Isentressi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The study showed that Isentress, given as tablets to be swallowed or chewable tablets, was safe in children and levels of the medicine obtained in the blood in children were similar to those obtained in adults.
Estonian: Laste uuring näitas neelatavate ja närimistablettidena manustatava Isentressi ohutust ja ravimi sisaldus laste veres oli sarnane sisaldusega täiskasvanute veres.
English: Isentress treatment led to a reduction in viral load and after 48 weeks 53% of the children had viral loads below 50 copies/ml.
Estonian: Isentressi ravi vähendas viiruskoormust ja 48 nädala pärast oli 53%-l lastest viiruskoormus alla 50 koopia/ml.
English: • Isentress has also been studied in a fifth study involving 126 HIV-1 infected children between 2 and 18 years whose existing treatment for HIV infection was not working.
Estonian: • Viiendas uuringus osales 126 HIV-1 nakkusega 2-18-aastast last, kelle olemasolev HIV-nakkuse ravi ei andnud tulemusi.
English: Patients also received the medicine Truvada (emtricitabine with tenofovir disoproxil).
Estonian: Patsiendid said lisaks ravimit Truvada (emtritsitabiin koos tenofoviirdisoproksiiliga).
English: Isentress can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Estonian: Isentress on retseptiravim ja ravi peab alustama HIV-infektsiooni ravis kogenud arst.
English: An overview of Isentress and why it is authorised in the EU
Estonian: Ülevaade ravimist Isentress ja ELis müügiloa väljastamise põhjendus
English: The main measure of effectiveness was the number of patients who had ‘undetectable' viral loads (below 50 copies per millilitre of blood) after 48 weeks.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel pärast 48-nädalast ravi viiruskoormust ei avastatud (alla 50 koopia vere ml kohta).
English: The studies compared Isentress with placebo (a dummy treatment), which were added to ‘optimised background therapy' (a combination of other HIV medicines chosen for each patient as it had the best chances of reducing the levels of HIV in the blood).
Estonian: Mõlemad lisati optimeeritud taustravile (muude HIV-ravimite kombinatsioon, mis valiti igale patsiendile individuaalselt, et HIV-sisaldus veres võimalikult efektiivselt väheneks).
English: After 48 weeks, 86% of the patients taking Isentress had viral loads below 50 copies/ml (241 out of 281), compared with 82% of those taking efavirenz (230 out of 282);
Estonian: Viiruskoormus oli pärast 48 nädalat alla 50 koopia/ml 86%-l Isentressi kasutanud patsientidest (241 patsienti 281st) ja 82%-l efavirensit kasutanud patsientidest (230 patsienti 282st).
English: The main measure of effectiveness was the reduction in the levels of HIV in the blood (viral load) after 16 weeks; 77% of the patients who took Isentress had viral loads below 400 copies/ml after 16 weeks, compared with 42% of those who took placebo.
Estonian: Efektiivsuse põhinäitaja oli vere HIV-sisalduse (viiruskoormuse) muutus pärast 16 ravinädalat; viiruskoormus oli pärast 16nädalast ravi alla 400 koopia/ml 77%-l Isentressi kasutanud patsientidest ja 42%-l platseebot saanud patsientidest.
English: Other information about Isentress:
Estonian: Muu teave Isentressi kohta
English: What benefits of Isentress have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Isentressi kasulikkus?
English: Isentress has been shown to be effective in helping control HIV when used with other HIV medicines.
Estonian: On tõendatud, et koos teiste HIV-ravimitega kasutatav Isentress on HIV-nakkuse ohjamisel efektiivne.
English: After 48 weeks, 89% (472 of 531) of those on the once daily dose and 88% (235 of 266) of those taking Isentress twice daily had viral loads less than 40 copies/ml;
Estonian: 48 nädala järel oli patsiente, kelle viiruskoormus oli alla 40 koopia/ml, Isentressi korra ööpäevas võtnutest 89% (472 patsienti 531st) ning ravimit kaks korda ööpäevas võtnutest 88% (235 patsienti 266st).
English: There have also been uncommon reports of rhabdomyolysis (breakdown of muscle fibres).
Estonian: Aeg-ajalt on teatatud ka rabdomüolüüsist (lihaskiudude lagunemine).
English: How is Isentress used?
Estonian: Kuidas Isentressi kasutatakse?
English: See also section 4.7.
Estonian: Vt ka punkt 4.7.
English: Ethanol 99.9%
Estonian: Etanool 99,9%
English: Do not broach more than 50 times.
Estonian: Ärge läbistage korki rohkem kui 50 korda.
English: Ireland.
Estonian: Iirimaa.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga ml sisaldab:
English: Avoid introduction of contamination during use.
Estonian: Kasutamise ajal vältida saastamist.
English: The MAH must ensure that the system of pharmacovigilance, as described in Part 1 of the marketing authorisation application, is in place and functioning before and whilst the product is on the market.
Estonian: Müügiloa hoidja peab tagama, et ravimiohutuse järelevalve süsteem, nagu on kirjeldatud müügiloa taotluse 1. osas, on kehtestatud ning toimib enne toote turuletulekut ja toote turustamise ajal.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 13/09/2011
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 13/09/2011
English: Tel: +353 (0)1 4515011 Fax: +353 (0)1 4621859
Estonian: Tel: +353 (0)1 4515011 Faks: +353 (0)1 4621859
English: Date of last renewal: 09/08/2016
Estonian: Müügiloa viimase uuendamise kuupäev: 09/08/2016
English: • Conditions or restrictions with regard to the safe and effective use of the medicinal product
Estonian: • Tingimused või piirangud, mis puudutavad ravimi ohutut ja tõhusat kasutamist
English: MANUFACTURER'S BATCH NUMBER LOT {number}
Estonian: TOOTJAPOOLNE PARTII NUMBER Lot {number}
English: Do not use in horses less than 6 weeks of age.
Estonian: Mitte kasutada alla 6-nädalastel hobustel.
English: Pigs: IM
Estonian: Sead: IM
English: 150 mg For the full list of excipients, see section 6.1.
Estonian: 150 mg Abiainete täielik loetelu on esitatud lõigus 6.1.
English: In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.
Estonian: Väga harvadel juhtudel võib esineda anafülaktilisi reaktsioone (sh raskeid ja surmavaid), mille korral tuleb teha sümptomaatilist ravi.
English: In the case of overdose, symptomatic treatment should be initiated.
Estonian: Üleannustamise korral alustada sümptomaatilist ravi.
English: Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06
Estonian: Farmakoterapeutiline rühm: mittesteroidsed põletiku- ja reumavastased ained (oksikaamid) ATCvet kood: QM01AC06
English: The active substance in Recocam 20 mg/ml solution for injection for cattle, pigs and horses is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Estonian: Toimeaine Recocam 20 mg/ml süstelahus veistele, sigadele ja hobustele on Komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 kirjeldatud lubatud aine:
English: The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No. 37/2010 indicates that no MRLs are required.
Estonian: Abiained, mis on loetletud ravimi omaduste kokkuvõtte lõigus 6.1, on lubatud ained, millele Komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 viidatakse kui ravimjääkide piirnorme mittenõudvatele.
English: In horses, a transient swelling at the injection site can occur but resolves without intervention.
Estonian: Hobustel võib süstekohal tekkida ajutine turse, kuid see kaob sekkumiseta.
English: Horses: IV
Estonian: Hobused: IV
English: To a minor extent it also inhibits collagen-induced thrombocyte aggregation.
Estonian: Vähemal määral pärsib see ka kollageeni põhjustatud trombotsüütide agregatsiooni.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10 loomal 10,000-st ravitud loomast) - Väga harv (vähem kui 1-l loomal 10,000-st ravitud loomast, kaasaarvatud harva esinevad üksikjuhud).>
English: Overdose (symptoms, emergency procedures, antidotes): In the case of overdose, symptomatic treatment should be initiated.
Estonian: Üleannustamine (sümptomid, esmaabi, antidoodid): Üleannustamise korral alustada sümptomaatilist ravi.
English: Bimeda Animal Health Limited, 2, 3 & 4 Airton Close, Tallaght, Dublin 24, Ireland.
Estonian: Bimeda Animal Health Limited, 2, 3 & 4 Airton Close, Tallaght, Dublin 24, Iirimaa.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals Accidental self-injection may give rise to pain.
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule Juhuslik süstimine iseendale võib tekitada valu.
English: Cattle and pigs: Can be used during pregnancy and lactation.
Estonian: Veised ja sead lubatud kasutada tiinuse ja laktatsiooni ajal.
English: EU/2/11/133/001 EU/2/11/133/002 EU/2/11/133/003
Estonian: EU/2/11/133/002
English: MARKETING AUTHORISATION NUMBERS EU/2/11/133/001-003
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/11/133/001-003
English: Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by E. coli endotoxin administration in calves, lactating cows and pigs.
Estonian: Meloksikaamil on ka antiendotoksilised omadused, sest on näidatud, et meloksikaam pärsib vasikatel, lakteerivatel veistel ja sigadel E. coli endotoksiini manustamisega tekitatud tromboksaan-B2 sünteesi.
English: Anhydrous citric acid Poloxamer 188
Estonian: Veevaba sidrunhape Poloksameer 188
English: Cattle and pigs:
Estonian: Veised ja sead
English: The metabolism in horses has not been investigated.
Estonian: Houstel ei ole ravimi metabolismi uuritud.
English: Vials contain 10 ml, 50 ml or 100 ml.
Estonian: Viaalid sisaldavad 10 ml, 50 ml ja 100 ml ravimit.
English: Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.
Estonian: Meloksikaami elimineerumise poolväärtusaeg pärast subkutaanset manustamist on 26 tundi ja 17,5 tundi vastavalt noorveistel ja lakteerivatel lehmadel.
English: Pack size of 1 Type I clear glass vial with Teflon coated bromobutyl rubber stoppers and sealed with an aluminium flip-off tear-off seal.
Estonian: Pakendis suurusega 1 on I tüüpi läbipaistev klaasviaal teflonkattega bromobutüülist kummikorgiga, mis on kaetud ärarebitava alumiiniumsulguriga.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after “EXP”.
Estonian: Ärge kasutage veterinaarravimit pärast kõlblikkusaega, mis on märgitud pakendil ja viaalil pärast EXP-d. Kõlblikkusaeg viitab selle kuu viimasele päevale.
English: Excipient: Ethanol 99.9% 150 mg
Estonian: Etanool 99.9% 150 mg Selge kollane lahus.
English: For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Estonian: Täiendavaks raviks poegimisjärgse sepsise ja tokseemia korral (mastiidi-metriidi-agalaktia sündroom) koos sobiva antibiootikumiraviga.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard Box: 10 ml, 50 ml or 100 ml vials
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Pappkarp: 10 ml, 50 ml või 100 ml viaalid
English: Do not use in cases of hypersensitivity to the active substance or to any of the excipient(s).
Estonian: Mitte kasutada, kui esineb ülitundlikkust toimeaine või ravimi ükskõik millis(t)e abiaine(te) suhtes.
English: After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 μg/ml and 2.7 μg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Estonian: Pärast ühekordset subkutaanset annust 0,5 mg meloksikaami/kg saavutati noorveistel ja lakteerivatel lehmadel Cmaxväärtused vastavalt 2,1 µg/ml ja 2,7 μg/ml 7,7 ja 4 tunni pärast.
English: The highest meloxicam concentrations are to be found in liver and kidney.
Estonian: Meloksikaami kontsentratsioon on kõige suurem maksas ja neerudes.
English: • Other conditions
Estonian: • Muud haigusseisundid
English: People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Estonian: Inimesed, kes on mittesteroidsete põletikuvastaste ravimite suhtes ülitundlikud, peaksid kokkupuudet veterinaarravimiga vältima.
English: CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Estonian: B. TARNIMIS-JA KASUTAMISTINGIMUSED VÕI PIIRANGUD
English: For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculoskeletal disorders, oral suspensions of meloxicam may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection.
Estonian: Põletiku ja valu leevendamiseks nii ägedate kui ka krooniliste luu- ja lihaskonna kahjustuste korral võib meloksikaami suukaudset lahust kasutada jätkuraviks üks kord annuses 0,6 mg meloksikaami 1 kg kehamassi kohta 24 tundi pärast süsti.
English: In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.
Estonian: Kui ravim ei vähenda hobustel koolikuid piisavalt, peab hobuse diagnoosi hoolikalt hindama, sest koolikute püsimine võib viidata kirurgilise sekkumise vajadusele.
English: After two intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.9 μg/ml was reached after 1 hour in pigs.
Estonian: Pärast kaht intramuskulaarset annust 0,4 mg meloksikaami/kg saavutati sigadel Cmax väärtus 1,9 μg/ml 1 tunni jooksul.
English: A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
Estonian: Vähem kui 10%-l kliinilistes uuringutes ravitud veistest täheldati pärast ravimi nahaalust manustamist kerget mööduvat turset süstekohal.
English: Horses: Do not use in pregnant or lactating mares.
Estonian: Hobused: Mitte kasutada tiinetel või imetavatel märadel.
English: Disposal: read package leaflet
Estonian: Hävitamine: vt pakendi infolehte
English: Shelf-life after first opening the container: 28 days Once broached, use by ….
Estonian: Kõlblikkusaeg pärast pakendi esmast avamist: 28 ööpäeva Pärast esmast avamist kasutada kuni….
English: Shelf-life after first opening the container: 28 days
Estonian: Kõlblikkusaeg pärast pakendi esmast avamist: 28 ööpäeva
English: 1 x 50 ml
Estonian: 1 × 50 ml
English: Cattle, pigs and horses.
Estonian: LOOMALIIGID Veised, sead ja hobused.
English: 1 x 100 ml
Estonian: 1 × 100 ml
English: Antiinflammatory agents/Nonsteroidal antiinflammatory agents
Estonian: Puuduvad Põletikuvastased ravimid / mittesteroidsed põletikuvastased ravimid
English: Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections
Estonian: Naatriumhüdroksiid (pH-regulaator) Vesinikkloriidhape (pH-regulaator) Süstevesi
English: LOT {number}
Estonian: Kõlblik kuni: {kuu/aasta}
English: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
Estonian: Põletiku ja valu leevendamiseks nii ägedate kui ka krooniliste luu- ja lihaskonna kahjustuste korral.
English: Excipient: Ethanol
Estonian: Etanool
English: Cattle: SC, IV
Estonian: Veised: SK, IV
English: • Conditions or restrictions regarding supply and use imposed on the marketing authorisation holder
Estonian: • Müügiloa hoidjale esitatud hanke- ja kasutustingimused ja -piirangud
English: Cattle: meat and offal: 15 days; milk: 5 days Pigs: meat and offal: 5 days
Estonian: Veised: liha ja söödavad koed: 15 ööpäeva; piim: 5 ööpäeva Sead: liha ja söödavad koed: 5 ööpäeva
English: Marketing authorisation holder and manufacturer responsible for batch release: Bimeda Animal Health Limited,
Estonian: Müügiloa hoidja ja partii vabastamise eest vastutav tootja: Bimeda Animal Health Limited, 2, 3 & 4 Airton Close,
English: Not authorised to use in horses producing milk for human consumption.
Estonian: Ei tohi kasutada hobustel, kelle piima kasutatakse inimtoiduks.